ESMO - Eur. Oncology· @myESMO · X·· 13 小时前评分70
正文 · 机器翻译
#ESMO26：DeLLphi-305 #ClinicalTrial 中总生存期显著改善；双特异性T细胞衔接器 #immunotherapy tarlatamab 联合 durvalumab 可能改变广泛期 #SCLC 的临床实践
🔗 https://ow.ly/6HyL50ZZlne
#InsightsbyESMO #LungCancer
401 浏览 · 3 赞 · 2 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com